Fadraciclib (CYC065)

CYC065, a novel CDK2/9 inhibitor, is an effective inducer of cell death and synergizes with BCL2 and BET inhibitors in B-cell lymphoma, including double-hit lymphomas. Proc. 107th Ann. Meeting AACR, 2016, Apr 16-20; New Orleans, LA, Abstract 1309.

CYC065, a novel CDK2/9 inhibitor, is an effective inducer of cell death and synergizes with BCL2 and BET inhibitors in B-cell lymphoma, including double-hit lymphomas. Proc. 107th Ann. Meeting AACR, 2016, Apr 16-20; New Orleans, LA, Abstract 1309. Read More »

Molecular basis for clinical development in basal-like triple-negative breast cancer. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res 2016;76 (4 Suppl): Abstract P5-03-10.

Molecular basis for clinical development in basal-like triple-negative breast cancer. Proceedings of the 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res 2016;76 (4 Suppl): Abstract P5-03-10. Read More »

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.